View Discovery

Clinical Pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)


TB Alliance, University of Auckland
GlaxoSmithKline
TB Alliance, University of Auckland, Merck & Co., Inc.
GlaxoSmithKline, TB Drug Accelerator
Microbiotix, Inc.

Phase 1


TB Alliance, Institute of Materia Medica
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF)
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Spero Therapeutics, LLC
GlaxoSmithKline
MicuRx Pharmaceuticals, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Institute of Materia Medica, CAMS & PUMC

Phase 2


Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Sequella, Inc
Sequella, Inc, TB Alliance
Médecins Sans Frontières
The Aurum Institute NPC, Calibr, The Scripps Research Institute
NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP
CDC TBTC, NIAID, NIH, DHHS, Boston University
Weill Medical College of Cornell University

Phase 3


University College, London, SPRINT TB (National University of Singapore)
Médecins Sans Frontières
Novartis
St. George's Hospital University of London